The acquisition is expected to allow the integration of Medpace’s therapeutic expertise and global reach with the device expertise of Symbios to offer clinical trial management solutions to medical device companies.

Medpace currently offers full service strategic consultation, Phase I-IV clinical trial management, bio-imaging, central laboratory, clinical pharmacology, and bioanalytical support for pharmaceutical and biotechnology companies, which Symbios will be now able to leverage to complement its service offering for medical device companies as well.

August Troendle, president and CEO of Medpace, said: “I am pleased to welcome Ryan Wilson and the Symbios team to Medpace as the head of our medical device business. Ryan and his team have built a successful company in the growing area of medical device research. They hold a unique position as a CRO dedicated to conducting medical device trials.

“The ability of Medpace to tap into this company for benefit of our existing and new Sponsors will be valuable as yet another service area for Medpace, and allow Symbios to benefit from our established global infrastructure.”